Effect of Tranexamic Acid on Hematologic Values and Blood Loss in Reverse Total Shoulder Arthroplasty

Table 1

Baseline data of the no TXA and TXA groups.

	No TXA (24)	TXA (24)	P value
Age (yr)	74.2 ± 4.4	73.2 ± 4.4	0.435
Sex (M : F)	6 : 18	3 : 21	0.461
Body mass index	25.1 ± 3.7	25.0 ± 3.4	0.896
Antiplatelet drug medication	8	6	0.525
American Shoulder and Elbow Surgeon score	41.3 ± 18.4	39.0 ± 18.2	0.679
Implant (A : B : C)	12 : 9 : 3	13 : 7 : 4	0.805
Cementing of humeral component	5	2	0.416
Subscapularis repair	19	21	0.701
Operation time (min)	66.1 ± 8.2	62.9 ± 11.9	0.282
Preop Hb (mg/L)	13.0 ± 1.2	13.4 ± 1.1	0.239
Preop Hct (L/L)	38.5 ± 3.3	40.1 ± 3.6	0.110

TXA = trenexamic acid; M = male; F = female; Preop = preoperative; Hb = hemoglobin; Hct = hematocrit; Data are presented as means ± standard deviations; Implant A = DJO Reverse Shoulder Prosthesis (DJO, Austin, TX, USA), B = Tornier reverse shoulder prosthesis (Tornier Inc, Stafford, TX, USA), C = Biomet Comprehensive Reverse Total Shoulder Replacement (Biomet Inc, Warsaw, IN, USA).